Aug 5 (Reuters) - GSK (GSK.L), opens new tab won the latest trial over claims that discontinued heartburn drug Zantac caused cancer, as a jury on Monday found that the drug was not responsible for ...

GSK has won its latest trial over whether its former best-selling ... known as NDMA that had been found in GSK’s heartburn drug Zantac; also known as ranitidine. The decision is the latest ...

Feb 25 (Reuters) - Boehringer Ingelheim has prevailed in the trial ... to heat. GSK, which faced the largest potential liability, in October agreed to settle about 80,000 Zantac lawsuits it ...

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of the heartburn drug Zantac ... facing a trial over the drug in Oakland ...

GSK has won its latest trial over whether its former best-selling drug caused ... from a contaminant known as NDMA that had been found in GSK’s heartburn drug Zantac; also known as ranitidine. The ...

UK-based GlaxoSmithKline PLC (GB:GSK) has won the latest U.S. trial concerning its heartburn drug Zantac (ranitidine), amid litigation over alleged cancer risks. The Florida State Court ruled in ...

GSK said on Monday its blood cancer drug Blenrep, when used as a second-line treatment in patients with myeloma, met its primary goal. GSK has won its latest trial over whether its former best ...